KLERTIS 50mg capsules medication leaflet

L01EX01 sunitinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors

Sunitinib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer, such as renal cell carcinoma and gastrointestinal stromal tumors. It works by blocking receptors involved in the growth and spread of tumor cells.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and undergo regular medical check-ups to monitor the response to treatment.

Patients should be aware of potential side effects, such as fatigue, nausea, or high blood pressure. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, diarrhea, and changes in blood pressure. In rare cases, severe reactions such as heart failure or tumor lysis syndrome may occur. Patients should be informed of these risks before starting treatment.

General data about KLERTIS 50mg

Substance: sunitinib

Date of last drug list: 01-06-2025

Commercial code: W68010001

Concentration: 50mg

Pharmaceutical form: capsules

Quantity: 28

Product type: generic

Price: 7244.26 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: EGIS PHARMACEUTICALS PLC - UNGARIA

Holder: EGIS PHARMACEUTICALS PLC. - UNGARIA

Number: 14023/2021/01

Shelf life: 30 months

Concentrations available for sunitinib

12.5mg, 25mg, 37.5mg, 50mg

Compensation lists for KLERTIS 50mg EGIS

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

7244.26 RON

1516.41 RON

5727.85 RON